According to IMARC Group, the global Pneumococcal Vaccine Market Size reached USD 10.26 Billion in 2025 and is projected to reach USD 15.51 Billion by 2034, expanding at a CAGR of 4.30% during 2026–2034. This strong growth trajectory reflects rising geriatric populations, expanding government immunization programs, growing burden of pneumococcal disease, and steady progress in next-generation conjugate vaccine platforms.

Pneumococcal Vaccine Industry Overview

Pneumococcal vaccines are biological preparations designed to protect against Streptococcus pneumoniae — a pathogen responsible for substantial global morbidity and mortality across all age groups. The market encompasses two principal product families: pneumococcal conjugate vaccines (PCVs) such as Prevnar 13, Prevnar 20, and Synflorix; and polysaccharide vaccines such as Pneumovax 23, serving distinct age groups and risk profiles across paediatric, adult, and immunocompromised populations.

The pneumococcal vaccine market sits at the intersection of public health policy, pharmaceutical innovation, and global immunization financing. Growth is anchored by expanding healthcare budgets in middle-income economies, aging demographics in OECD markets, and multilateral funding through Gavi, the Vaccine Alliance. Technological evolution toward higher-valency PCVs and recombinant platforms is reshaping the competitive landscape and extending the product lifecycle across developed and emerging markets.

Key vaccine and product categories shaping pneumococcal vaccine market share include:

•      Pneumococcal Conjugate Vaccines (PCVs): The dominant vaccine type commanding 71.6% market share in 2025, encompassing Prevnar 13 (PCV13), Prevnar 20 (PCV20), Synflorix (PCV10), and higher-valency clinical candidates

•      Pneumococcal Polysaccharide Vaccines (PPSVs): Led by Pneumovax 23, accounting for 28.4% of the market, serving adults with specific risk profiles with broad 23-serotype coverage

•      Prevnar 13: The dominant individual product at 48.7% global share, cornerstone of paediatric immunization in 100+ countries with progressive transition of adult demand toward Prevnar 20

•      Synflorix: GSK's 10-valent PCV holding 29.6% share, anchored by Gavi-supported pediatric programs across 40+ eligible low- and middle-income countries

•      Next-Generation Platforms: PCV20, PCV21 (Capvaxive), and clinical-stage candidates V116/V117 expanding serotype coverage for adult immunization

Global Market Overview & Pneumococcal Vaccine Market Statistics

Below are the key pneumococcal vaccine market statistics drawn from IMARC Group's comprehensive market analysis:

Base Year - 2025

Historical Period - 2020–2025

Forecast Period - 2026–2034

Market Size in 2025 - USD 10.26 Billion

Market Forecast in 2034 - USD 15.51 Billion

Market Growth Rate (2026–2034) - 4.30% CAGR

Leading Vaccine Type - Pneumococcal Conjugate Vaccine (71.6% share, 2025)

Leading Product Type - Prevnar 13 (48.7% share, 2025)

Second Product - Synflorix (29.6% share, 2025)

Third Product- Pneumovax 23 (21.7% share, 2025)

Largest Region - North America (41.8% share, 2025)

Fastest Growing Region - Middle East & Africa (~5.8% CAGR)

Fastest Growing End-User - Adults (~4.9% CAGR through 2030)

Global Doses (2025) - ~180 million doses (conjugate + polysaccharide)

Request for a Sample Report for Detailed Pneumococcal Vaccine Market Insights: https://www.imarcgroup.com/pneumococcal-vaccine-market/requestsample

Key Market Drivers & Pneumococcal Vaccine Market Trends in 2026

Several powerful forces are shaping pneumococcal vaccine market growth and driving expansion across global healthcare markets:

1. Aging Population and Elderly Vulnerability to Pneumococcal Disease

The aging global population represents one of the most significant structural drivers of the pneumococcal vaccine market. The WHO projects the population aged 60 and above to reach 2.1 billion by 2050. Older adults face markedly elevated risk of invasive pneumococcal disease (IPD), driving sustained demand for adult-indicated PCV20 and PCV21 formulations across North America, Europe, and Japan. The U.S. ACIP's 2024 expanded eligibility recommendations broadening adult pneumococcal vaccination to adults aged 50+ — including the previously uncovered 50–64 age cohort — represent a landmark shift in the adult immunization segment.

2. Government Immunization Programs and Multilateral Procurement

Government-led immunization programs remain the backbone of pneumococcal vaccine market size expansion globally. More than 150 countries have integrated PCVs into routine infant immunization schedules. Gavi-supported pediatric coverage reached an estimated 82% in eligible low-income nations in 2024, creating structured multi-year procurement for Synflorix and Pneumosil. PAHO's Revolving Fund underpins procurement in Latin America, while Asia-Pacific countries including China (NIP inclusion), India (UIP scale-up), and Japan (adult PCV expansion) are driving significant volume growth.

3. Rising Burden of Pneumococcal Disease and Public Health Priority

Streptococcus pneumoniae remains a leading cause of community-acquired pneumonia and a major pediatric pathogen globally. The WHO attributes nearly 20 million sepsis cases in children under 5 to this bacterium annually, reinforcing the public-health case for expanded PCV coverage. Growing awareness of pneumococcal disease as a key contributor to global morbidity and mortality is driving heightened government investment in pneumococcal vaccination programs — a central pneumococcal vaccine market trend across both developed and emerging healthcare markets.

4. Advancements in Higher-Valency Conjugate Vaccine Technology

Continuous pharmaceutical innovation is reshaping the pneumococcal vaccine market share landscape through the development of higher-valency conjugate vaccines. Pfizer's PCV20 (Prevnar 20) and Merck's Capvaxive (PCV21) — the first 21-valent conjugate vaccine specifically designed for adults, approved by the U.S. FDA in June 2024 — are widening serotype coverage and lifting average selling prices across the adult segment. PCV21's coverage of serotypes responsible for approximately 85% of invasive pneumococcal disease in U.S. adults aged 50+ positions it as a significant commercial opportunity. Next-generation candidates including Vaxcyte's V116 (24-valent) and V117 (30-valent) are in late-stage clinical development.

5. Expansion of Adult Immunization Programs

Adult immunization represents the fastest-growing segment within the pneumococcal vaccine market, advancing at an estimated 4.9% CAGR through 2030. ACIP's 2024 shared clinical decision-making recommendation for adults aged 50+ and parallel EMA guidance updates are driving pharmacy-led catch-up vaccination campaigns. The progressive transition from PCV13 to PCV20 and PCV21 in adult immunization schedules is elevating average revenue per dose and expanding the addressable population substantially beyond prior eligibility thresholds.

6. Emerging Market Domestic Manufacturing and Procurement Shifts

Domestic vaccine manufacturers in India and China are fundamentally reshaping pneumococcal vaccine market trends in lower-income markets. Serum Institute's Pneumosil — which received WHO prequalification in December 2019 — and Walvax Biotechnology's PCV13-TT are providing cost-optimized alternatives for LMIC procurement. These domestic players have reshaped pricing dynamics in Africa and Asia, supported by Gavi's market-shaping strategy emphasizing supplier diversification. Serum Institute signed a long-term supply agreement of up to 100 million doses through Gavi-backed mechanisms, underscoring the scale and importance of this manufacturing shift.

Key Market Segmentation

By Vaccine Type

Pneumococcal Conjugate Vaccines — Largest Segment (71.6% Share in 2025)

Pneumococcal conjugate vaccines lead the global pneumococcal vaccine market with a 71.6% share in 2025. Demand is driven by broad paediatric adoption across 150+ national immunization programs and progressive expansion into adult indications through PCV20 and PCV21. Higher-valency platforms are accelerating average selling prices in the U.S. and EU, while PCV13 continues to dominate infant schedules in emerging markets. Co-administration approvals with influenza and RSV vaccines, and sensor-based cold-chain monitoring improvements, are further strengthening commercial positioning for conjugate formulations.

Pneumococcal Polysaccharide Vaccines — Complementary Segment (28.4% Share)

Polysaccharide vaccines account for 28.4% of the pneumococcal vaccine market, led by Pneumovax 23 with its broad 23-serotype coverage. Although volume is smaller than conjugate formulations, this segment retains relevance for adults with specific risk profiles. ACIP guidance continues to position PPSV23 as complementary to PCVs in adult sequential schedules, sustaining steady demand through 2034, particularly for risk-based indications in immunocompromised and high-risk adult populations.

By Product Type

Prevnar 13 — Dominant Product (48.7% Share in 2025)

Prevnar 13 is the dominant product globally, commanding 48.7% of pneumococcal vaccine revenue in 2025. Pfizer's flagship PCV13 remains the cornerstone of paediatric immunization in 100+ countries and has progressively transitioned adult demand toward Prevnar 20. Commercial continuity is supported by broad private-payer coverage in the U.S. and government procurement in Europe and Japan. The product's established global distribution, regulatory approvals, and reimbursement footprint ensure continued leadership through the forecast period.

Synflorix — Second Product (29.6% Share)

Synflorix, GSK's 10-valent conjugate vaccine, holds 29.6% of global product share. It is a key supply asset in Gavi-supported pediatric programs, serving more than 40 eligible countries under multi-year agreements. Its cost-competitive positioning and WHO prequalification status make it the preferred option across Sub-Saharan Africa and parts of Asia-Pacific under Gavi procurement.

Pneumovax 23 — Adult-Focused Polysaccharide Vaccine (21.7% Share)

Merck's Pneumovax 23 accounts for 21.7% of the market, primarily serving adult populations in developed markets through sequential PCV-PPSV23 schedules and risk-based indications for immunocompromised individuals, elderly patients, and those with chronic medical conditions.

By Distribution Channel

Non-Governmental Organizations (NGOs) — Leading Channel

NGOs — primarily Gavi and UNICEF — constitute the leading distribution channel, responsible for approximately 65% of global paediatric pneumococcal vaccine volume. Multilateral procurement through Gavi's Advance Market Commitment (AMC) and UNICEF's supply division provides structured, multi-year demand visibility that enables manufacturers to invest in capacity expansion and pricing commitments for low-income markets.

Government Authorities

Government immunization authorities represent a significant distribution channel across middle- and high-income markets. National programs in North America, Europe, and Asia-Pacific procure PCVs through direct government channels for routine infant immunization and adult catch-up programs, reflecting mandated coverage requirements and public health policy commitments.

Distribution Partner Companies

Commercial distribution partners serve private-market channels in developed markets, facilitating pharmacy-led adult immunization — a fast-growing distribution mechanism particularly relevant for Prevnar 20 and PCV21 adult programs in the U.S. and EU.

By End User

The market is segmented between pediatric and adult end users. Pediatrics has historically been the primary demand driver, anchored by routine infant immunization in 150+ countries. However, adults represent the fastest-growing end-user segment at an estimated 4.9% CAGR through 2030, propelled by ACIP-expanded eligibility, EMA guidance updates, and broad uptake of Prevnar 20 and Capvaxive across pharmacy and healthcare provider channels.

Regional Market Analysis

North America — Largest (41.8% Share)

United States & Canada; CDC/ACIP routine infant and adult immunization schedules; Medicare Part B reimbursement for adult PCVs; broad private-payer coverage; 2024 ACIP expansion broadening adult eligibility to 50+ including previously uncovered 50–64 cohort; rapid PCV20 and PCV21 uptake; Canadian NACI-aligned provincial programs.

Europe (25.6% Share)

Germany, France, UK, Italy, Spain, Russia; centralized EMA approvals; national immunization programs; aging population driving adult PCV demand; June 2025 ECDC reinforcement of adult vaccination guidance for 65+ individuals; progressive Prevnar 20 rollout across EU markets; Brexit adding dual EU-UK compliance complexity.

Asia-Pacific (21.4% Share)

China (NIP inclusion), India (UIP scale-up), Japan (adult PCV expansion), South Korea, Australia, Indonesia; domestic manufacturing from Serum Institute (Pneumosil) and Walvax reshaping procurement economics; growing medical tourism and healthcare infrastructure investment; rising adult immunization focus.

Latin America (6.2% Share)

Brazil and Mexico lead; PAHO Revolving Fund procurement underpinning paediatric coverage; Brazil's PNI (National Immunization Program) and Mexico's universal pediatric coverage; growing adoption of higher-valency conjugate formulations; progressive regulatory harmonization with global standards.

Middle East & Africa (~5.0% Share, ~5.8% CAGR — Fastest Growing)

GCC national programs (UAE, Saudi Arabia); Sub-Saharan Africa Gavi-supported PCV introductions; domestic fill-finish expansion; growing health infrastructure investment; highest regional growth rate at approximately 5.8% CAGR through 2034, supported by expanding Gavi coverage and multi-year supply agreements.

Connect for Detailed Segmentation Analysis – Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=3133&flag=C

Leading Players in the Pneumococcal Vaccine Industry

The global pneumococcal vaccine market is highly concentrated at the top, with Pfizer, Merck, and GSK collectively accounting for approximately 80–85% of global revenue in 2025. Pfizer alone holds an estimated 55–60% share through the combined Prevnar 13 and Prevnar 20 franchises. Key companies profiled in the IMARC Group report include:

•      Pfizer Inc. — Market Leader: Prevnar 13 and Prevnar 20 (PCV20); January 2024 EMA CHMP marketing authorization for pediatric Prevnar 20 use extending into infant and child immunization schedules

•      Merck & Co. Inc. — Major Player: Capvaxive (PCV21, FDA-approved June 2024 — first 21-valent adult conjugate vaccine) and Pneumovax 23 (PPSV23); USD 200M+ in initial U.S. revenue within six months of Capvaxive launch

•      GSK Plc. — Major Player: Synflorix (PCV10); multi-year Gavi procurement contracts serving 40+ eligible countries

•      Sanofi — Challenger: R&D collaborations and combination vaccine platforms in PCV development

•      Cyrus Poonawalla Group / Serum Institute of India — Emerging: Pneumosil (PCV13); WHO prequalification; up to 100M doses via Gavi supply agreements; reshaping LMIC pricing

•      Walvax Biotechnology Co. Ltd — Emerging: PCV13-TT; China domestic leadership; Asia-Pacific reach; cost-competitive LMIC positioning

•      Panacea Biotec — Emerging: NuVac-23, NuCoVac-11; India UIP supply; combination product portfolio

•      Vaxcyte — Clinical Stage Challenger: V116 (24-valent) and V117 (30-valent) built on cell-free XpressCF platform; November 2023 Lonza manufacturing partnership for V116 commercial scale-up; Phase 3 readouts expected 2026–2027

The report includes comprehensive competitive analysis covering market structure, player positioning, top winning strategies, competitive dashboard, and a company evaluation quadrant assessing pneumococcal vaccine market share dynamics among leading global players.

Latest News and Developments

June 2025: The European Centre for Disease Prevention and Control (ECDC) reinforced adult vaccination guidance emphasizing pneumococcal conjugate vaccine uptake among individuals aged 65 and above, further supporting Prevnar 20 and future adult PCV rollout across EU member states.

January 2024: Pfizer received marketing authorization from the EMA's CHMP for its 20-valent pneumococcal conjugate vaccine (PCV20) for pediatric use, extending Prevnar 20 into infant and child immunization schedules and significantly expanding the addressable paediatric market for higher-valency conjugate formulations in Europe.

June 2024: Merck secured FDA approval for Capvaxive (PCV21) for adults aged 18+, establishing the first 21-valent pneumococcal conjugate vaccine specifically designed for adult immunization. Capvaxive covers serotypes responsible for approximately 85% of invasive pneumococcal disease in U.S. adults aged 50+, positioning it as a landmark competitor in the adult immunization market.

November 2023: Vaxcyte signed a commercial-scale manufacturing agreement with Lonza to support V116 launch preparations, highlighting the capital-intensity and strategic importance of late-stage higher-valency PCV development. V116 (24-valent) and V117 (30-valent) represent potentially transformative products for adult immunization with Phase 3 readouts expected through 2026–2027.

Ongoing — Gavi Market Shaping: Serum Institute's Pneumosil and GSK's Synflorix continue to expand coverage under Gavi's multi-supplier procurement strategy, with Gavi-supported pediatric coverage reaching an estimated 82% in eligible low-income nations in 2024. Gavi's emphasis on supplier diversification is fostering competition and supporting more affordable access to pneumococcal vaccines across Sub-Saharan Africa and South Asia.

Industry Value Chain Analysis

Raw Materials

Polysaccharide antigens, carrier proteins (CRM197, tetanus toxoid), adjuvants, lipid excipients sourced from specialty biologics suppliers globally

R&D & Clinical Trials

Antigen selection, conjugation chemistry, Phase I–III trials — led by Pfizer, Merck, GSK, Sanofi, Vaxcyte, and Serum Institute of India

Manufacturing

Large-scale fermentation, conjugation, fill-finish, QA release — Pfizer (McPherson USA, Ireland), Merck (Durham NC), GSK (Belgium), Serum Institute (Pune India)

Regulatory Approval

FDA, EMA, PMDA, MHRA, and WHO prequalification — critical gating stage for multi-market global launch

Distribution Channels

Government immunization authorities, multilateral NGOs (Gavi, UNICEF, PAHO), and commercial distribution partners serving developed-market private channels

End Users

Paediatric patients (infants and children under 5), adults aged 50+, immunocompromised individuals, elderly populations, and healthcare workers

Frequently Asked Questions (FAQs)

What is driving the growth of the Pneumococcal Vaccine Market?

Pneumococcal vaccine market growth is primarily driven by aging global populations with elevated vulnerability to invasive pneumococcal disease, expanding government-led immunization programs across 150+ countries, rising global pneumococcal disease burden, advancements in higher-valency conjugate vaccine technology (PCV20, PCV21), growing adult immunization adoption, and Gavi-supported expansion of paediatric coverage in emerging economies.

What is the Pneumococcal Vaccine Market Size?

The global pneumococcal vaccine market size reached USD 10.26 Billion in 2025 and is forecast to reach USD 15.51 Billion by 2034, growing at a CAGR of 4.30% during 2026–2034, according to IMARC Group's latest market analysis.

Which vaccine type leads the Pneumococcal Vaccine Market Share?

Pneumococcal conjugate vaccines hold the largest pneumococcal vaccine market share at 71.6% in 2025, driven by broad paediatric adoption across 150+ national immunization programs and progressive expansion into adult indications through PCV20 and PCV21.

Which product holds the largest share within the Pneumococcal Vaccine Market?

Prevnar 13 holds the largest product-level share at 48.7% in 2025, supported by routine paediatric use in 100+ countries and Pfizer's established global distribution, reimbursement, and government procurement infrastructure.

Which region dominates the Pneumococcal Vaccine Market?

North America leads the global pneumococcal vaccine market with a 41.8% revenue share in 2025, underpinned by CDC/ACIP immunization schedules, strong Medicare and private-payer reimbursement, and rapid adoption of Prevnar 20 and Capvaxive in adult immunization programs.

What are the key Pneumococcal Vaccine Market Trends shaping the future?

Key pneumococcal vaccine market trends include the shift toward higher-valency conjugate platforms (PCV20, PCV21, and pipeline candidates V116/V117), expansion of adult immunization programs following ACIP and EMA guidance updates, domestic manufacturing scale-up in India and China reshaping emerging-market procurement economics, next-generation recombinant platforms from Vaxcyte, combination and simplified dosing schedule research, and digital cold-chain innovation improving vaccine management in low-income markets.

What is the future outlook for Pneumococcal Vaccine Market Growth?

The pneumococcal vaccine market is expected to sustain steady growth through 2034, driven by continued expansion of higher-valency conjugate platforms, the adult immunization segment transitioning to become a core demand pillar, domestic manufacturers in India and China intensifying competition in LMIC tenders, and progressive inclusion of PCVs in national immunization programs across Asia-Pacific, Africa, and Latin America.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Healthcare, Vaccines & Immunology, Technology, Chemicals and Materials, Agriculture, Food & Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104

Email: sales@imarcgroup.com